255 completed, 71 terminated, 50 unknown, 47 recruiting. 229 Phase 2, 148 Phase 1, 66 Phase 3, 28 Not applicable, 6 Early Phase 1.
Follow Fallopian Tube Cancer: new trials by email Literature Review of Fallopian Tube Cancer trials Research Report on Fallopian Tube Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer QLS5132, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 420 | 2026-12-01 | 2026-11-09 |
| A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) R-DXd, Bevacizumab, Carboplatin - Ovarian Cancer, Peritoneal Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 646 | 2026-10-07 | 2026-11-10 |
| Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions Routine-care metastasis-directed radiotherapy - Cervical Cancer, Gynecologic Cancer | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 500 | 2026-10-06 | 2026-10-23 | |
| A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) R-DXd, Bevacizumab - Fallopian Tube Cancer, Primary Peritoneal Cancer | Phase 3 | Not yet recruiting | Daiichi Sankyo | 600 | 2026-10-01 | 2026-09-01 |
| Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers BG-C9074, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | BeOne Medicines | 600 | 2026-10-01 | 2026-09-10 |
| A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) R-DXd, Bevacizumab - Ovarian Cancer, Ovarian Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 802 | 2026-09-18 | 2026-11-05 |
| A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer BL-M07D1, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 404 | 2026-07-01 | 2026-06-29 |
| Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer AZD5335, Itraconazole - Fallopian Tube Cancer, Ovarian Cancer | Phase 1 | Recruiting | AstraZeneca | 32 | 2026-01-26 | 2026-09-29 |
| Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors Romiplostim N01, All-trans retinoic acid - Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia | Phase 2 | Recruiting | Peking University People's Hospital | 220 | 2025-12-22 | 2026-05-14 |
| Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer Cirtuvivint, Olaparib - Endometrioid Ovarian Cancer, Primary Peritoneal Cancer | Phase 1 | Recruiting | University of Colorado, Denver | 50 | 2025-12-08 | 2026-07-24 |
| A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. Carboplatin, Mirvetuximab Soravtansine, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | AbbVie | 140 | 2025-11-21 | 2026-10-20 |
| Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Utidelone capsule 75mg/m2/d QD, Utidelone capsule 40mg/m2/d BID, Utidelone capsule 50mg/m2/d BID - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Not yet recruiting | Beijing Biostar Pharmaceuticals Co., Ltd. | 72 | 2025-09-01 | 2025-06-30 |
| A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 450 | 2025-08-04 | 2026-07-07 |
| A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies IMGN151, Carboplatin, Bevacizumab - Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer | Phase 2 | Recruiting | AbbVie | 377 | 2025-07-30 | 2026-10-01 |
| Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 3 | Recruiting | Imunon | 500 | 2025-07-09 | 2026-10-30 |
| Surgery for Relapsed Ovarian Cancer in Precision surgery/chemotherapy, Iparomlimab/Tuvonralimab - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Gynecologic Oncology Group | 33 | 2025-07-01 | 2025-06-27 |
| Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer Ubamatamab, Bevacizumab, Cemiplimab - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 397 | 2025-05-28 | 2026-11-06 |
| Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer KELIM, Carboplatin plus Paclitaxel, Interval debulking surgery - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | The University of Hong Kong | 126 | 2025-05-22 | 2025-07-02 |
| A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer Zirabev - Non-small Cell Lung Cancer, Metastatic Colorectal Cancer | Withdrawn | Pfizer | 2025-05-16 | 2025-03-19 | ||
| The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer Olaparib - Ovarian Cancer, Epithelial Cancer | Phase 1 / Phase 2 | Recruiting | The Netherlands Cancer Institute | 55 | 2025-05-01 | 2026-03-10 |
Showing 20 of 473. Sign in to see all of them.
Fallopian Tube Neoplasms (473) · Ovarian Neoplasms (385) · Carcinoma, Ovarian Epithelial (218) · Endometrial Neoplasms (57) · Uterine Cervical Neoplasms (43) · Neoplasms (31) · Breast Neoplasms (29) · Recurrence (28) · Carcinoma, Non-Small-Cell Lung (21) · Vulvar Neoplasms (19) · Stomach Neoplasms (18) · Colorectal Neoplasms (17) · Sarcoma (17) · Vaginal Neoplasms (16) · Brenner Tumor (15)
Adnexal Diseases (473) · Female Urogenital Diseases (473) · Female Urogenital Diseases and Pregnancy Complications (473) · Genital Diseases (473) · Genital Diseases, Female (473) · Urogenital Diseases (473) · Urogenital Neoplasms (473) · Fallopian Tube Diseases (471) · Genital Neoplasms, Female (471) · Neoplasms by Site (471) · Endocrine Gland Neoplasms (454) · Endocrine System Diseases (454) · Gonadal Disorders (454) · Ovarian Diseases (448) · Neoplasms (442)
Carboplatin (94) · Paclitaxel (91) · Bevacizumab (56) · Topotecan (29) · liposomal doxorubicin (27) · Gemcitabine (26) · Cisplatin (23) · pembrolizumab (20) · Cyclophosphamide (16) · Docetaxel (16) · olaparib (13) · mirvetuximab soravtansine (12) · niraparib (12) · Drug Therapy (11) · rucaparib (10)
National Cancer Institute (NCI) (27) · Memorial Sloan Kettering Cancer Center (24) · Gynecologic Oncology Group (15) · Dana-Farber Cancer Institute (14) · Masonic Cancer Center, University of Minnesota (12) · M.D. Anderson Cancer Center (10) · University Health Network, Toronto (9) · AbbVie (8) · Shanghai Gynecologic Oncology Group (8) · pharmaand GmbH (7) · AGO Study Group (6) · Amgen (6) · Merck Sharp & Dohme LLC (6) · Abramson Cancer Center at Penn Medicine (5) · Beth Israel Deaconess Medical Center (5)
United States (318) · United Kingdom (55) · Canada (53) · Spain (46) · France (37) · Australia (36) · Belgium (35) · Germany (34) · Italy (34) · China (32) · South Korea (26) · Israel (18) · Poland (16) · Austria (15) · Denmark (15)
Paul Sabbatini, MD (10) · Ursula Matulonis, MD (6) · Amy D. Tiersten, MD (4) · Angeles A Secord, MD (4) · Levi S. Downs, MD (4) · Amit Oza, M.D. (3) · Andreas du Bois, MD, PhD (3) · Clare Shaw, Phd (3) · Dennis Chi, MD (3) · Hal W. Hirte, MD, FRCP(C) (3) · Ignace B. Vergote, MD, PhD (3)
PMID 37185961, PMID 35170751, PMID 35397664, PMID 37407274, PMID 20818904, PMID 31685558, PMID 36459691, PMID 36608308, PMID 37227734, PMID 11181662, PMID 12082455, PMID 12082456, PMID 12829663, PMID 14615449, PMID 14645425, PMID 14656276, PMID 15131031, PMID 15661234, PMID 15699482, PMID 16014111, PMID 16135465, PMID 16150481, PMID 16368439, PMID 16394300, PMID 16412499, PMID 16882940, PMID 16959305, PMID 17330838, PMID 17704410, PMID 17910981, PMID 17918264, PMID 18191187, PMID 18336399, PMID 18451240, PMID 18538834, PMID 18768432, PMID 18829088, PMID 19058838, PMID 19138791, PMID 19238149, PMID 19264351, PMID 19464730, PMID 19671873, PMID 19767092, PMID 19819917, PMID 19922985, PMID 19922989, PMID 20022092, PMID 20357034, PMID 20733132
U10CA027469 (5), U10CA032102 (5), 2009 (3), 2016 (3), 2023 (3), 2025 (3), 2017 (2), 2019 (2), N01CM62201 (2), N01CM62203 (2), N01CM62204 (2), N01CM62209 (2), P01CA111412 (2), P30CA008748 (2), P30CA043703 (2)